Non Invasive Methods for Diagnosis and Progression of Diabetes, Kidney, Urological, Hematological and Digestive Diseases and Hypertensive Disorders (R01) | Apply Online

Opportunity Summary:

This NIH funding opportunity (PA-09-181) supports research projects that develop or apply noninvasive or minimally invasive methods to improve how a wide set of diseases are detected, characterized, diagnosed, and followed over time. The central idea is to move beyond traditional, more invasive diagnostics by using advanced imaging and related technologies to see what is happening inside the body in real time, measure biological changes earlier, and track how patients respond to therapy. A major emphasis is on creating practical tools that can identify people who are at risk before disease becomes clinically obvious, and on improving monitoring so clinicians and researchers can judge whether a treatment is working without relying on burdensome procedures.

The participating NIH institutes are the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute (NHLBI). The disease areas named in the announcement are broad but connected by common needs in early detection and progression monitoring. They include type 1 and type 2 diabetes; acute and chronic kidney disease; liver diseases; urologic conditions; hematologic disorders; digestive diseases; and a range of endocrine and metabolic disorders, including obesity and its complications. Hypertensive disorders are also a key focus, including obesity-related hypertension and hypertension driven by renal and vascular abnormalities. In practice, this means proposals can span everything from identifying early kidney injury in diabetes, to better ways of assessing liver pathology without biopsy, to improved phenotyping of vascular or renal contributors to high blood pressure.

A recurring theme in the FOA is the push for better biomarkers, especially surrogate markers that could serve as endpoints in clinical trials. The announcement explicitly calls for new and robust surrogate markers that can stand in for harder-to-measure clinical outcomes, helping trials run faster, with clearer signals and potentially smaller sample sizes. Along the same lines, it encourages tools that can characterize normal versus diseased tissue in vivo, meaning measurements taken in living systems rather than extracted tissue samples. This reflects a translational goal: methods should ideally help both basic understanding of disease biology and practical decision-making in clinical research and, eventually, patient care.

The technologies envisioned are not limited to traditional radiology. The FOA highlights molecular imaging and functional imaging, as well as imaging approaches with improved spatial resolution, chemical specificity, or time resolution. It also points to omics and sensing approaches that can be used in a noninvasive or minimally invasive way, including metabolomics, proteomics, and genomics when they are leveraged to monitor metabolic or physiological events. In addition, it calls out newer spectroscopic techniques and sensor array technologies, implying interest in innovative platforms that can detect subtle biochemical signals, continuous physiologic changes, or molecular signatures that correlate with disease onset, progression, or response to treatment. Taken together, the scope supports projects that might integrate multiple data streams, such as combining imaging readouts with molecular signatures, or pairing functional measures with high-specificity chemical detection.

The mechanism of support for this announcement is the NIH Research Project Grant (R01), which is designed for substantial, hypothesis-driven research programs and technology development efforts that require a full project structure, clear aims, and a plan for rigorous validation. The FOA also notes that smaller, developmental or exploratory projects that fit the same scientific scope could be pursued through the NIH Parent R21 mechanism, rather than through this specific R01 announcement. In other words, this opportunity is positioned for more mature or comprehensive projects under the R01 pathway, while still acknowledging that earlier-stage work may be better suited to R21.

In terms of administrative details, the opportunity was posted May 1, 2009, with an original and final closing date of May 7, 2012, and it was archived June 7, 2012. It did not require cost sharing or matching. Although it is now archived, the eligibility language is expansive and reflects standard NIH openness to a wide range of applicant organizations. Eligible applicants included public and private institutions of higher education, nonprofits (including 501(c)(3) and other nonprofit structures), for-profit organizations (including small businesses and other for-profits), and multiple levels of government (state, county, local, special districts), along with tribal organizations and public housing authorities. The eligibility section also explicitly included certain mission-focused institution types such as Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, faith-based and community-based organizations, and even non-U.S. (foreign) entities and regional organizations, reflecting NIH policy that allows foreign components or foreign organizations to apply when scientifically justified.

Overall, this FOA is essentially a targeted call for new tools and validated measures that can reduce reliance on invasive sampling, improve early detection and risk stratification, and provide stronger, more actionable indicators of disease activity and treatment response across diabetes, kidney, digestive, urologic, hematologic, metabolic, and hypertension-related conditions. The scientific expectations are aligned with NIH priorities: innovation in measurement technology, strong biological and clinical relevance, and credible paths toward biomarkers or imaging-based measures that can be used in living subjects to accelerate both mechanistic research and clinical translation.

Browse more business programs for Diabetes Research

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Food and Nutrition Health

Next opportunity: Empire Ranch Preservation, Interpretation, and Education

Previous opportunity: Computational Science Research for Ice Sheet Modeling

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 09 181

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 09 181) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 181", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.